Pfizer Halts Late-Stage Trial of Potential Lymphoma Drug

For the second time this week, a major pharmaceutical company has pulled the plug on a trial testing a potential treatment for non-Hodgkin's lymphoma.

Earlier in the week, pharmaceutical giant Lilly halted the Phase III trial of a candidate for treating patients with diffuse large B-cell lymphoma.

Pfizer to test drug against other blood cancers

And now word comes from Pfizer Inc. saying that they, too, have halted a late-stage trial of an investigational drug for the treatment of aggressive non-Hodgkin's lymphoma after independent monitors of the trial concluded that the drug was unlikely to offer patients any survival benefits. This will not stop the company from testing the drug inotuzumab ozogamicin against other blood cancers, however.

In a statement released to the press, Pfizer's senior vice president of clinical development and medical affairs for its oncology business unit, Mace Rothenberg, said, "Hematologic cancers are a complex group of diseases with more than 70 different types of lymphomas, leukemias or myelomas that require unique treatment options."

No known safety issues with the drug

The trial had been testing inotuzumab in combination with the monoclonal antibody rituximab in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who were not candidates for intensive high-dose chemotherapy. This arm of the trial was being compared against two other arms – one that received rituximab plus Treanda and one that received rituximab and gemcitabine.

The monitors indicated that there were no safety problems with the drug, just inefficacy. Since conclusion of the trial would have begun the process of obtaining regulatory approval, and since monitors concluded that the combination was no better in terms of overall survival than the other two regimens, Pfizer decided to pull the plug.

It is not known which blood cancers the drug will be tested against next.

Source: Pfizer

More Articles

More Articles

Lymphoma patients may have the option to participate in clinical trials, gaining access to an experimental treatment before it is widely available...

Since there are several subtypes of T cell lymphoma, there will necessarily be several non-specific T cell lymphoma...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

After surviving lymphoma treatments, patients should be on the lookout for late effects. These are symptoms that arise well after treatment has...

Canine lymphoma is a fairly common cancer in American dogs. The most commonly seen lymphoma in America is a type called Lymphosarcoma, although...

Advances in the treatment of Hodgkin's lymphoma have resulted in remarkable survival rates, even for...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...

The short answer: both. Let's begin with a simple definition of radiation: Radiation is the energy emitted from an energy source. That energy...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

When you consider that the adult human body has anywhere from 300 to 700 lymph nodes, the better question might not be where ARE they located, but...

This entry looks at a non-Hodgkin's lymphoma called true histiocytic lymphoma (THL), also referred to as diffuse histiocytic lymphoma, and...

Lymphomatous meningitis [LM], also known as leukemic meningitis, is an extremely serious peripheral cancer that attacks the tissue that covers the...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Intravascular lymphoma is a subtype of 'Lymphoma', an umbrella term that loosely refers to several dozen...